The data becomes not just invalid, but dangerously misleading
Many report that adding BPC-157 during dose escalation phases helps them push through the adjustment period with less discomfort
Tabata et al., 1999) are illustrative for the pertinence of the poorly resolved problem, illustrative for the diversity of the carriers (i.e., hyaluronate gel carrier (Wang and Aspengberg, 1996), alginate/heparinsacharose microspheres and films (Yu et al., 1998), cellulose gel (Thorn and Aspenberg, 1993), defective form of Pseudomonas exotoxin (Siegall et al., 1994), fibrin adhesive carrier (Walter et al., 1996), biodegredable hydrogen gelatin (Tabata et al., 1999), natural coral, and collagen (Sikiric et al., 2018), there is an inescapable diversity of the carriers and thereby, an evident diversity of the obtained beneficial effects, and disable conclusion
If you are exploring peptide therapy, work with a qualified clinician who can help you build a plan that matches your physiology and goals
